Purpose: Evaluate bleeding patterns for the Liletta V R levonorgestrel 52 mg intrauterine system (IUS) using the World Health Organization Belsey definitions. Material and methods: This prospective multicenter trial evaluates the efficacy and safety of Liletta V R (Clinicaltrials.gov NCT00995150). We evaluated bleeding patterns for 1700 nulliparous and multiparous women using a daily diary completed by participants for the first 2 years and by questionnaire every 3 months thereafter. We assessed amenorrhea rates over 3 years and the proportion of subjects with infrequent, frequent, prolonged and irregular bleeding per 90-day reference period over 2 years for the entire study population as well as comparing nulliparous and parous women and obese and non-obese women. Results: Amenorrhea rates at 1 and 3 years in levonorgestrel 52 mg IUS users were 19 and 37%, respectively. The infrequent bleeding rate increased from 14% in the first 90 days to 30% at the end of Year 1, and was maintained at the same rate through Year 2. Frequent, prolonged and irregular bleeding declined to low levels by the end of the first year. Discontinuation for bleedingrelated complaints occurred in 35 (2.1%, 95% CI 1.3-2.7%) women during the first 36 months; only one subject discontinued for amenorrhea (in Year 2). Outcomes did not vary for nulliparous versus parous or obese versus non-obese women. Conclusions: Among Liletta users, amenorrhea and infrequent bleeding become more prevalent over time and amenorrhea rates continue to increase after the first year of use. Bleeding patterns do not differ significantly by parity or by obesity-status. Discontinuation for bleeding concerns is uncommon with this product.
Introduction
The World Health Organization (WHO) recommends reporting hormonal contraception bleeding patterns using the Belsey criteria [1] . These descriptors present a global picture of bleeding patterns over 90-day intervals ( Table 1) . For levonorgestrel intrauterine system (IUS) products, the Belsey method has been used to describe bleeding patterns for the lower dose products, but not for the levonorgestrel 52 mg IUS. Moreover, the limited bleeding data available for levonorgestrel 52 mg IUS users were primarily derived from Scandinavian multiparous women, 75% of whom had used intrauterine contraception previously [2] . The recent development of a newer levonorgestrel 52 mg IUS has provided the opportunity to obtain a detailed collection of bleeding data from a very large and diverse population. In this report, we describe the bleeding patterns with the Liletta V R levonorgestrel 52 mg IUS using the WHO Belsey criteria. Providing this information can allow a more standardised understanding of potential differences in bleeding patterns between different levonorgestrel IUS products.
Materials and methods
We present a secondary analysis of data from the ACCESS IUS multicenter, Phase 3, open-label clinical trial of the Liletta levonorgestrel 52 mg IUS [Medicines360, San Francisco, CA and Allergan, Irvine, CA; Liletta V R is a registered trademark of Odyssea Pharma SPRL (Belgium), an Allergan affiliate]. Liletta is marketed for contraception as Levosert TM and Donasert TM in Europe using this same data. The methods of this study have been reported previously [3] . A central or local Institutional Review Board for each center approved the study. All women signed written informed consent before study participation.
Briefly, investigators at 29 clinical sites in the USA enrolled healthy, non-pregnant, sexually active, nulliparous and parous women aged 16-45 years (inclusive) who desired a hormonal IUS for contraception. Participants had to report regular menstrual cycles every 21-35 days with a variation of typical cycle length of no more than 5 days. Those women currently using hormonal contraception could not be using it for cycle control and reported a typical history of regular cycles prior to their most recent hormonal contraception initiation. Women recently using progestin injectable contraception could not enter the study if the prior injection was within the preceding 9 months, or 6 months if the subject had two spontaneous menstrual cycles (minimum of three menses) that met criteria for normal menstrual cycles.
After subjects completed screening and enrollment (IUS placement), follow-up included visits at 1, 3, 6 and 12 months and then every 6 months thereafter. Telephone contact was initiated at Month 9 and occurred at the 3-month interval between scheduled visits. Subjects completed a daily diary for the first 2 years to indicate the greatest amount of bleeding that day as none, spotting, light flow, normal flow, or heavy flow based on their own subjective impression. After 2 years, subjects were asked at each visit or telephone contact to describe their bleeding pattern over the preceding 3 months.
For the analysis in this report, we only included women with successful IUS placement who provided bleeding data through at least the first 90 days or who discontinued for bleeding-related complaints in the first 90 days. We limited the description of prolonged, frequent, infrequent and irregular bleeding with the levonorgestrel 52 mg IUS to 2 years because we only had daily diary data for the first 2 years of use. The bleeding data collected after 2 years was sufficient to precisely evaluate amenorrhea rates, which we did through 3 years. We assessed all bleeding patterns over 90-day intervals using the WHO Belsey criteria ( Table 1 ) [1] . We also compared the patterns between nulliparous and parous women as well as non-obese and obese women, with obesity defined as a body mass index 30 kg/m 2 . We used Fisher's exact testing for comparisons of proportions with p values .05 considered significant.
Results
Of the 1751 women enrolled, 1714 (97.9%) had successful placement: 14 (0.8%) of these women discontinued prior to 90 days for non-bleeding-related complaints leaving 1700 women in the analysis. Participant characteristics are presented in Table 2 . Overall, bleeding data was available at the end of 1, 2 and 3 years for 1448 (85.2%), 1178 (69.3%) and 935 (55.0%) women, respectively.
Discontinuation for bleeding complaints occurred in 35 (2.1%, 95% CI 1.3-2.7%) levonorgestrel 52 mg IUS users cumulatively during the first 36 months, most commonly during Months 6-18 (Table 3 ). Reasons provided by women who primarily discontinued for bleeding-related complaints included heavy flow (12 women) and pattern-related issues including irregular bleeding (12 women), prolonged flow (7 women) and increased frequency (3 women); only one subject discontinued for amenorrhea (in year 2). Few women were lost to follow-up with 68 (4.0%), 55 (3.2%) and 21 (1.2%) in years 1, 2 and 3, respectively.
Bleeding patterns
Amenorrhea rates in levonorgestrel 52 mg IUS users increased over 3 years (Table 4 and Figure 1 ). Infrequent bleeding was reported by 14% of levonorgestrel 52 mg IUS users in the first 90 days, increased to 30% at the end of Year 1, and was maintained at the same rate through Year 2. Frequent bleeding occurred in 26% of levonorgestrel 52 mg IUS users in the first 90 days and quickly declined to fewer than 10% in the second 90-day reference period. Prolonged bleeding declined in a similar manner from 51% in the first 90 days to 10% in the second 90-day reference period. Irregular bleeding was reported by 38% of women in the first 90 days, declining to 14% in the second 90 days and 6% by the end of the first year ( Table 5 and Figure 1 ).
Bleeding patterns for nulliparous versus parous women and obese versus non-obese women are presented in Tables 4  and 5 . We found sporadic and inconsistent differences related to frequency of bleeding. Although nulliparous women had lower rates of infrequent bleeding in the first 90 days as compared to parous women, the opposite is true in the 90 days at the end of Year 1 and no differences were present in the second 90 days or at the end of Year 2. Lower rates of frequent bleeding are found in parous women during the first and second 90 day periods but no differences are present at 1 or 2 years. Overall, no trends are present which suggest that parity or obesity status affects bleeding pattern in any consistent pattern.
Discussion
Our findings demonstrate that amenorrhea rates increase each year with continued use of the Liletta levonorgestrel 52 mg IUS. Rates of frequent and prolonged bleeding decline rapidly in the first few months of levonorgestrel IUS use, with rates of 10% or less during months four through six of use. The patterns overall demonstrate that levonorgestrel 52 mg IUS users are likely to experience frequent, irregular and/or prolonged bleeding episodes in the first 90 days that quickly diminish to light and less prolonged bleeding for most women. The bleeding patterns do not vary significantly or consistently based on parity or obesity status. Removal rates for bleeding-related complaints are very low over 3 years (2.1%) with about one-third of such discontinuations due to heavy flow, one-third due to irregular bleeding and one-third related to prolonged or frequent bleeding. Only includes women who had successful IUS placement and at least one follow-up visit at 90 days; two subjects discontinued for bleeding-related complaints prior to 90 days. Discontinuation as % of study population uses the total N of 1700 as denominator for all calculations; discontinuation as % of women entering time period uses the number entering that time period as the denominator. IUS: intrauterine system. This study is the first to use the WHO Belsey criteria to describe bleeding patterns with a levonorgestrel 52 mg IUS in a large, prospectively collected dataset. Lower dose levonorgestrel IUS products introduced to the market within the past decade have reported bleeding patterns using these criteria [4, 5] . Standardised reporting of bleeding with contraceptive use has been endorsed for decades [1, 6] . Yet, the current prescribing information for the three different doses of levonorgestrel IUS products (13.5, 19.5 and 52 mg) provides information in different ways, even among dose- Table 1 for definitions of bleeding patterns; the number of subjects for each column represents the number with data for the 90 days at the end of the interval. IUS: intrauterine system. equivalent products [4] [5] [6] [7] [8] . As such, clinically relevant differences in bleeding patters are difficult to distill. By presenting our results using the Belsey criteria, we can begin to assess potential differences between the products, and provide information that is easily conveyed to patients.
A comparison of our results with previously published data indicates that women using lower dose levonorgestrel 13.5 [5] and 19.5 mg [4] IUS products have lower rates of amenorrhea and infrequent bleeding and have higher rates of irregular bleeding than women using the Liletta levonorgestrel 52 mg IUS; rates of frequent and prolonged bleeding are similar for all three doses. Women using levonorgestrel 13.5, 19.5 and 52 mg IUS products have very similar frequent and prolonged bleeding pattern rates over the first few years. Such a comparison is limited by differences in study participant populations. The lower dose levonorgestrel IUS studies included a mix of women from 11 countries (Argentina, Canada, Chile, Finland, France, Hungary, Mexico, the Netherlands, Norway, Sweden, and USA) whereas this current study was performed exclusively in the USA [9] . Additionally, the lower dose levonorgestrel IUS studies had 39.2% nulliparous women with a mean BMI of 25.3 kg/m 2 [9] whereas this current study had 57.5% nulliparous women with a mean BMI of 27.3 kg/m 2 . These characteristics, as well as other differences, could account for some variations in bleeding patterns and limit comparisons among these studies.
To truly understand general similarities and differences in bleeding patterns between levonorgestrel IUS products with different doses, a randomised study would be required for a more precise comparison. Although a Phase 2 randomised trial comparing the levonorgestrel 13.5, 19.5 and 52 mg IUS (Mirena V R , Bayer HealthCare Pharmaceuticals, Whippany, NJ) has been published, the report only included amenorrhea rates at the end of 1 year [10] . The study included 239, 245, and 254 European women in the three groups, respectively with 216 (90.4%), 213 (86.9%) and 218 (85.8%) women, respectively completing 1 year of use. The authors report amenorrhea rates of 12.7, 18.9, and 23.6% for 13.5, 19.5 and 52 mg devices, respectively (p ¼ .012 for levonorgestrel 13.5 mg versus 52 mg and p ¼ .30 for levonorgestrel 19.5 mg versus 52 mg). However, this study had limited statistical power to fully compare amenorrhea rates.
Conclusions
This study represents the largest dataset to systematically evaluate bleeding patterns among levonorgestrel 52 mg IUS users over 2 years. Women who use the Liletta levonorgestrel 52 mg IUS commonly experience amenorrhea or infrequent bleeding with continued duration of use; frequent and irregular bleeding decrease significantly after the first 90 days of use. Bleeding patterns do not vary consistently based on parity or between non-obese and obese women. The information can be helpful when providing counseling to women about what bleeding patterns to expect with levonorgestrel 52 mg IUS products.
